

Oteseconazole: Adis Evaluation

Key Points

- An azole antifungal agent that is being developed by Mycovia Pharmaceuticals for the treatment of fungal infections
- Received its first approval on 28 April 2022 in the USA
- Approved to reduce the incidence of RVVC in females with a history of RVVC who are NOT of reproductive potential

Summary

Oteseconazole (VIVJOA™) is an orally administered azole antifungal agent developed by Mycovia Pharmaceuticals for the treatment of fungal infections.

It inhibits cytochrome P450 (CYP) 51, thereby affecting the formation and integrity of the fungal cell membrane, but has a low affinity for human CYP enzymes due to its tetrazole metal-binding group.

Oteseconazole is the first agent to be approved (in April 2022) for recurrent vulvovaginal candidiasis (RVVC) in the USA, where it is indicated to reduce the incidence of RVVC in females with a history of RVVC who are NOT of reproductive potential.

Clinical development for the treatment of onychomycosis, and invasive and opportunistic infections is ongoing.

This summary represents the opinions of the [author/authors]. For a full list of declarations, including funding and author disclosure statements, please see the full text online. © Springer Nature Switzerland AG 2022.